Sutro Biopharma (STRO) Share-based Compensation (2017 - 2025)

Sutro Biopharma's Share-based Compensation history runs 9 years deep, the most recent figure standing at $1.7 million for Q4 2025.

• In Q4 2025, Share-based Compensation fell 72.02% year-over-year to $1.7 million; the TTM figure through Dec 2025 stood at $14.0 million (down 43.26% YoY), while the FY2025 annual figure was $14.0 million, down 43.26% from the prior year.
• Share-based Compensation came in at $1.7 million for Q4 2025 at Sutro Biopharma, up from $1.6 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $7.0 million in Q1 2022 to a low of $1.6 million in Q3 2025.
• A 5-year average of $5.7 million and a median of $6.0 million in 2023 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation soared 123.1% in 2021 and tumbled 76.29% in 2025, its largest moves.
• Sutro Biopharma's Share-based Compensation stood at $6.9 million in 2021, then declined by 15.03% to $5.9 million in 2022, then rose by 6.34% to $6.2 million in 2023, then declined by 4.95% to $5.9 million in 2024, then plunged by 72.02% to $1.7 million in 2025.
• According to Business Quant data, Share-based Compensation over the past three periods registered $1.7 million, $1.6 million, and $5.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.

Peer Comparison